Zimmer Biomet has completed its $177 million acquisition of Monogram Technologies, an orthopedic robotics company.
The acquisition expands Zimmer’s suite of orthopedic robotics by adding Monogram’s semi-autonomous robotic technologies, according to an Oct. 7 news release from Zimmer Biomet.
Monogram Technologies developed a CT-based, semi-autonomous and AI-navigated total knee arthroplasty robot, which earned FDA clearance in March. The technology is expected to be commercialized with Zimmer Biomet implants by 2027.
In addition, Monogram began a clinical study for a fully autonomous version of the robotic technology in July.
Zimmer Biomet entered into a definitive agreement to acquire Monogram in July. Under the agreement, Zimmer paid $4.04 per share in cash to acquire all outstanding shares of Monogram’s stock.
With the acquisition completed, Monogram will be delisted from the NASDAQ, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
